Inflammatory indexes as prognostic biomarkers in advanced triple negative breast cancer patients - Summary - MDSpire

Inflammatory indexes as prognostic biomarkers in advanced triple negative breast cancer patients

  • By

  • Caterina Gianni

  • Emanuela Scarpi

  • Eva Blondeaux

  • Michela Palleschi

  • Filippo Merloni

  • Lorenzo Gasperoni

  • Fabio Puglisi

  • Elena Collovà

  • Palma Pugliese

  • Francesco Cognetti

  • Irene Giannubilo

  • Tommaso Ruelle

  • Lucia Del Mastro

  • Claudia Bighin

  • Antonino Musolino

  • Ugo De Giorgi

  • July 15, 2026

Share

Objective:

To investigate the association between inflammatory indexes (NLR, PLR, MLR, and SII), clinical characteristics, and survival outcomes in patients with metastatic TNBC.

Approach:
  • Study Design: Retrospective-prospective, observational multicenter analysis.
  • Patient Population: 114 consecutive patients with a diagnosis of metastatic TNBC.
  • Data Collection: Clinical characteristics and inflammatory indexes were evaluated at diagnosis.
Key Findings:
  • Median progression-free survival (PFS) was 8.6 months (95% CI 6.5–9.6); median overall survival (OS) was 17.7 months (95% CI 13.7–23.9).
  • High NLR (≥3), MLR (≥0.34), PLR (≥210), and SII (≥836) were significantly associated with lower PFS and OS.
  • In multivariable analysis, the number of metastatic sites, NLR, SII, and MLR were significant predictors of OS.
Interpretation:

Inflammatory ratios may serve as prognostic biomarkers in metastatic TNBC.

Limitations:
  • Results need validation in larger prospective studies.
  • Study population may not represent all metastatic TNBC patients treated with contemporary therapies.
Conclusion:

NLR, PLR, SII, and MLR are associated with PFS and OS in metastatic TNBC.

Original Source(s)

Inflammatory indexes as prognostic biomarkers in advanced triple negative breast cancer patients

  • by Caterina Gianni, Emanuela Scarpi, Eva Blondeaux, Michela Palleschi, Filippo Merloni, Lorenzo Gasperoni, Fabio Puglisi, Elena Collovà, Palma Pugliese, Francesco Cognetti, Irene Giannubilo, Tommaso Ruelle, Lucia Del Mastro, Claudia Bighin, Antonino Musolino, Ugo De Giorgi

  • July 15, 2026

Related Content

Inside VIVEbiotech’s Work with Zelluna on TCR-NK Cell Therapy

VIVEbiotech CEO Jon Alberdi lifts the lid on an eight-year collaboration focused on GMP lentiviral vectors for off-the-shelf solid tumor therapies

  • July 14, 2026

  • 4 min
Functional brain connectivity correlates of pain relief during virtual reality exposure in cancer patients

Sarcopenia in breast cancer: prognostic values and emerging therapeutic strategies